What are the potential drug interactions with flunarizine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Potential Drug Interactions with Flunarizine

Flunarizine has several important drug interactions that require careful monitoring, particularly with medications affecting the central nervous system, cardiovascular system, and those with similar side effect profiles.

Key Drug Interactions

Central Nervous System Interactions

  • Flunarizine may increase the risk of extrapyramidal symptoms and depression when combined with antipsychotics or other medications that affect dopaminergic pathways 1
  • Concomitant use with benzodiazepines or other CNS depressants may enhance sedative effects, leading to increased risk of drowsiness and impaired cognitive function 2
  • Monoamine oxidase inhibitors (MAOIs) should be avoided with flunarizine due to potential for severe interactions affecting blood pressure and CNS function 2

Cardiovascular Interactions

  • Combination with beta-blockers or other calcium channel blockers may potentiate hypotensive effects 2
  • Epinephrine should not be used to treat hypotension caused by flunarizine overdose, as this combination may paradoxically worsen hypotension 2
  • Caution is needed when combining with other medications that prolong QT interval due to potential additive effects 2

Hormonal Interactions

  • Flunarizine may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, particularly after initial dosing and dose escalations 1
  • Women using oral contraceptives should consider switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation 1

Special Populations and Considerations

Elderly Patients

  • Elderly patients are at higher risk for developing extrapyramidal symptoms and should be monitored closely when taking flunarizine 3
  • Lower starting doses are recommended in elderly patients to minimize side effects 4
  • Digoxin can be safely co-administered with flunarizine in elderly patients if clinically indicated 1

Patients with Neurological Conditions

  • Patients with seizure disorders require careful monitoring as flunarizine may exacerbate focal seizure disorders 1
  • In patients with migraine, caution should be used when combining flunarizine with other preventive medications that could increase weight or exacerbate depression 1

Monitoring Recommendations

  • Regular monitoring of weight is recommended as flunarizine commonly causes weight gain 4
  • Monitor for signs of depression and extrapyramidal symptoms, particularly in long-term use 1
  • Assess for sedation and cognitive effects, especially when initiating therapy or when combined with other CNS depressants 2
  • Consider liver function monitoring in patients on multiple medications 2

Clinical Pearls

  • The 5mg dose of flunarizine has a better side effect profile than the 10mg dose while maintaining efficacy for many patients 4
  • Side effects of flunarizine are dose-dependent; starting with lower doses may improve tolerability 4
  • Flunarizine has a long half-life and accumulates in adipose tissue, which may lead to prolonged drug interactions even after discontinuation 5
  • When treating migraine, flunarizine should be given for at least 3-4 months before its efficacy can be properly assessed in some patients 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Flunarizine and essential tremor in the elderly.

Archives of gerontology and geriatrics, 1996

Research

Flunarizine in migraine prophylaxis: efficacy and tolerability of 5 mg and 10 mg dose levels.

Cephalalgia : an international journal of headache, 1990

Research

Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation.

Cephalalgia : an international journal of headache, 1985

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.